116 related articles for article (PubMed ID: 33283718)
1. [Clinical Efficacy of ALL-2005 and ALL-2009 Regimen and Factors Influencing Prognosis of Newly Diagnosed ALL Patients Aged between 10-18 Years Old].
Li X; Si SY; Cai JJ; Qu WJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Dec; 28(6):1904-1911. PubMed ID: 33283718
[TBL] [Abstract][Full Text] [Related]
2. [Outcome of children with T cell acute lymphoblastic leukemia treated with Chinese Children Leukemia Group acute lymphoblastic leukemia (CCLG-ALL) 2008 protocol].
Liu XM; Chen XJ; Zou Y; Wang SC; Wang M; Zhang L; Chen YM; Yang WY; Guo Y; Zhu XF
Zhonghua Er Ke Za Zhi; 2019 Oct; 57(10):761-766. PubMed ID: 31594062
[No Abstract] [Full Text] [Related]
3. [Clinical Biological Characteristics and Prognostic Factors of Children with Ph
Liu ZY; Sun Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Dec; 27(6):1754-1760. PubMed ID: 31839034
[TBL] [Abstract][Full Text] [Related]
4. [Efficacy and Safety of Intensive Maintenance Chemotherapy Regimen for Treatment of Children and Adolescents with Lymphoblastic Lymphoma for Stage III-IV].
Liu YF; Liu SW; Sun XJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Apr; 28(2):524-528. PubMed ID: 32319390
[TBL] [Abstract][Full Text] [Related]
5. [Influence of MRD Status in Newly Diagnosed MM Patients with VGPR and Above after Treatment on Clinical Prognosis].
Yu X; Zhang KJ; Wu XJ; Shi LJ; Lin HZ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Oct; 28(5):1631-1636. PubMed ID: 33067965
[TBL] [Abstract][Full Text] [Related]
6. [Interim results of a multicenter cohort study for Chinese Children Leukemia Group-acute lymphoblastic leukemia 2018 regimen].
Chinese Children Leukemia Group
Zhonghua Er Ke Za Zhi; 2023 Oct; 61(10):874-880. PubMed ID: 37803853
[No Abstract] [Full Text] [Related]
7. [Clinical effect of CCLG-ALL2008 regimen in treatment of children and adolescents aged >10 years with acute lymphoblastic leukemia].
Lan Y; Chen XJ; Zou Y; Ruan M; Zhu XF
Zhongguo Dang Dai Er Ke Za Zhi; 2019 May; 21(5):405-410. PubMed ID: 31104652
[TBL] [Abstract][Full Text] [Related]
8. [Long-term clinical effect of the CCLG-ALL2008 regimen in treatment of childhood acute lymphoblastic leukemia with different molecular biological features].
Chen XJ; Zou Y; Liu XM; Yang WY; Guo Y; Ruan M; Liu F; Chen YM; Zhang L; Wang SC; Zhu XF
Zhongguo Dang Dai Er Ke Za Zhi; 2019 Sep; 21(9):890-893. PubMed ID: 31506148
[TBL] [Abstract][Full Text] [Related]
9. [Treatment outcome of childhood standard-risk and median-risk acute lymphoblastic leukemia with CCLG-2008 protocol].
Liu X; Zou Y; Wang H; Chen X; Ruan M; Chen Y; Yang W; Guo Y; Liu T; Zhang L; Wang S; Zhang J; Liu F; Cai X; Qi B; Chang L; Zhu X
Zhonghua Er Ke Za Zhi; 2014 Jun; 52(6):449-54. PubMed ID: 25190166
[TBL] [Abstract][Full Text] [Related]
10. [Clinical Prognostic Factors Analysis of Initially Treated AML Children with t(8;21)/RUNX1-RUNX1T1
Fan GL; Jiang PJ; Yuan M
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Oct; 28(5):1510-1515. PubMed ID: 33067946
[TBL] [Abstract][Full Text] [Related]
11. [Clinical Efficacy and Prognostic Factors of Newly Diagnosed Children[JP] with Burkitt Lymphoma Treated by High-Dose and Short-Course Modified LMB Regimen ± Rituximab].
Wang BT; Dang HB; Wei YJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Apr; 28(2):529-534. PubMed ID: 32319391
[TBL] [Abstract][Full Text] [Related]
12. [Long-Term Outcome of 940 Children with Newly Diagnosed Acute Lymphoblastic Leukemia Treated with CCLG-ALL 2008: A Prospective Single Center Study in China].
Zou Y; Chen XJ; Liu XM; Guo Y; Yang WY; Chen YM; Zhang L; Zhu XF
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Aug; 28(4):1075-1080. PubMed ID: 32798380
[TBL] [Abstract][Full Text] [Related]
13. A survival study and prognostic factors analysis on acute promyelocytic leukemia at a single center.
Xin L; Wan-jun S; Zeng-jun L; Yao-zhong Z; Yun-tao L; Yan L; Chang-chun W; Qiao-chuan L; Ren-chi Y; Ming-zhe H; Jian-xiang W; Lu-gui Q
Leuk Res; 2007 Jun; 31(6):765-71. PubMed ID: 17007927
[TBL] [Abstract][Full Text] [Related]
14. [Influence of Combination with 1q21 Amplification or-No in Patients with Newly Diagnosed MM on the Clinical Effecacy of Bortezomib-based induction chemotherapy and Long-Term Prognosis of Patients].
Gu WW; Wang JS; Mu K; Ren G
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Aug; 28(4):1251-1255. PubMed ID: 32798407
[TBL] [Abstract][Full Text] [Related]
15. [Multicenter clinical trial of acute lymphoblastic leukemia in elder children and adolescents].
Zhang N; Shen SH; Wang NL; Li H; Yang JW; Shao JP; Jiang H; Tang JY
Zhonghua Xue Ye Xue Za Zhi; 2018 Sep; 39(9):717-723. PubMed ID: 30369180
[No Abstract] [Full Text] [Related]
16. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group.
Yanada M; Takeuchi J; Sugiura I; Akiyama H; Usui N; Yagasaki F; Kobayashi T; Ueda Y; Takeuchi M; Miyawaki S; Maruta A; Emi N; Miyazaki Y; Ohtake S; Jinnai I; Matsuo K; Naoe T; Ohno R;
J Clin Oncol; 2006 Jan; 24(3):460-6. PubMed ID: 16344315
[TBL] [Abstract][Full Text] [Related]
17. Bone marrow recurrence after initial intensive treatment for childhood acute lymphoblastic leukemia.
Rivera GK; Zhou Y; Hancock ML; Gajjar A; Rubnitz J; Ribeiro RC; Sandlund JT; Hudson M; Relling M; Evans WE; Pui CH
Cancer; 2005 Jan; 103(2):368-76. PubMed ID: 15599932
[TBL] [Abstract][Full Text] [Related]
18. [Clinical Efficacy of NOPHO-AML 2004 Regimen for Treatment of Children with Acute Myelocytic Leukemia (Non-M3)].
Qiu KY; Liao XY; Huang K; Li Y; Weng WJ; Xu HG; Fang JP; Wu RH; Zhou DH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Apr; 26(2):375-381. PubMed ID: 29665901
[TBL] [Abstract][Full Text] [Related]
19. [Comparison of Clinical Outcomes between P190 and P210 Trans-cripts in Adult Ph Chromosome Positive Acute Lymphoblastic Leukemia in the New Era of TKI].
Qiu LL; Lu YJ; Jing Y; Yu L; Liu DH; Wang LL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Apr; 24(2):369-74. PubMed ID: 27150994
[TBL] [Abstract][Full Text] [Related]
20. [Effect of Modified LMB 89± Rituximab Regimen on Long-Term Benefits for Patients's with Burkitt Lymphoma].
Tan L; Xie Y; Yang J; Liu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Jun; 28(3):872-875. PubMed ID: 32552950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
